Aug. 14 at 3:02 PM
$ADIL Here’s an update on Adial’s Phase 3 trial:
The FDA approved Adial’s adaptive Phase 3 design, which includes details about the patient population, the key outcomes to measure, how to identify different groups of patients, and how to increase the chances of getting the trial to work.
Adial is also working with Cytel to use machine learning to find the groups of patients who are most likely to benefit from ADO4.
In terms of manufacturing, Adial has agreements with Thermo Fisher and Cambrex to provide the drugs needed for the trial. They’ve already completed demonstration batches and are planning to start registration batches soon.
As for finances, Adial has
$5.9 million in cash on hand (as of June 30, 2025), which should be enough to keep the trial running until the second quarter of 2026.
